Approximately 50% of patients with newly diagnosed sarcoma eventually die of disease. The purpose of the Developmental Research Program of the MSKCC SPORE in Soft Tissue Sarcoma is to support innovative translational research projects in sarcoma. The translational research projects in this program aim to use knowledge of animal and human sarcoma biology to develop and test interventions related to improving diagnosis, prognosis, and treatment of pafients with soft fissue sarcoma. This program will allow us to respond quickly to new opportunifies in translational research and will help us recruit new scientific talent into our SPORE and, more broadly, into sarcomarelevant research.
The specific aims of the Developmental Research Program are: 1) to provide seed funding for innovative, investigator-initiated research in the biology, pathogenesis, progression, and natural history of sarcoma, 2) to fund research with exceptional potential to advance the translational research goals of the SPORE, and 3) to establish a mechanism for strategic interactions with other SPOREs and other major national and international research centers. We are budgeting $450,000 yeariy for this program including $50,000 from the SPORE award itself and $400,000 in MSKCC institutional funds. The priority for funding will be those inifiafives considered most creafive and of the highest scientific quality. Preference will be given to projects that complement the long-term research goals of the SPORE and advance our translational research objecfives. The executive committee can also solicit and fund experimental or clinical initiatives that address an urgent and specific need in the MSKCC SPORE in Soft Tissue Sarcoma program or a unique research opportunity. The internal scientific advisory committee, under the chairmanship of Murray F. Brennan, MD, will review applications to determine priorities for use of these funds and will annually select projects for one to two years of funding. The projects that appear most promising after two years of funding will be considered for incorporation into the SPORE as Research Projects, either in current or future funding cycles.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA140146-04
Application #
8515351
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
4
Fiscal Year
2013
Total Cost
$43,244
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Katabi, Nora; Xu, Bin; Jungbluth, Achim A et al. (2018) PLAG1 immunohistochemistry is a sensitive marker for pleomorphic adenoma: a comparative study with PLAG1 genetic abnormalities. Histopathology 72:285-293
Argani, Pedram; Pawel, Bruce; Szabo, Sara et al. (2018) Diffuse Strong BCOR Immunoreactivity Is a Sensitive and Specific Marker for Clear Cell Sarcoma of the Kidney (CCSK) in Pediatric Renal Neoplasia. Am J Surg Pathol 42:1128-1131
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Moore, Amanda R; Ran, Leili; Guan, Youxin et al. (2018) GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Rep 22:2455-2468
Dickson, Brendan C; Antonescu, Cristina R; Argyris, Prokopios P et al. (2018) Ectomesenchymal Chondromyxoid Tumor: A Neoplasm Characterized by Recurrent RREB1-MKL2 Fusions. Am J Surg Pathol 42:1297-1305
Weinreb, Ilan; Bishop, Justin A; Chiosea, Simion I et al. (2018) Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland. Am J Surg Pathol 42:442-452
Kao, Yu-Chien; Flucke, Uta; Eijkelenboom, Astrid et al. (2018) Novel EWSR1-SMAD3 Gene Fusions in a Group of Acral Fibroblastic Spindle Cell Neoplasms. Am J Surg Pathol 42:522-528
Bartenstein, Diana W; Coe, Taylor M; Gordon, Samantha C et al. (2018) Lipofibromatosis-like neural tumor: Case report of a unique infantile presentation. JAAD Case Rep 4:185-188
Chen, Yu; Chi, Ping (2018) Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. J Hematol Oncol 11:78
Owosho, Adepitan A; Estilo, Cherry L; Huryn, Joseph M et al. (2018) A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors. Head Neck Pathol 12:151-159

Showing the most recent 10 out of 169 publications